Core Insights - The launch of Ryanodex® represents a significant advancement in emergency care for malignant hyperthermia in India, aiming to provide hope and critical treatment options [1][3] - The initiative is supported by key stakeholders, including the Indian Society of Anesthesiologists, which has been instrumental in building a national preparedness platform for managing malignant hyperthermia emergencies [2][4] Company Overview - Perin Healthcare is focused on delivering critical medicines and medical solutions across India, partnering with global innovators to enhance emergency preparedness and patient outcomes [6] - Eagle Pharmaceuticals is a fully integrated pharmaceutical company dedicated to developing innovative medicines that improve patients' lives [7] - ACA Pharma specializes in fast-track regulatory pathways and market access, facilitating patient access to medications in a timely manner across Greater China and Southeast Asia [8] Product Information - Ryanodex® (dantrolene sodium for injection) is FDA-approved for treating and preventing malignant hyperthermia, particularly in high-risk patients [9] Event Highlights - A nationwide professional launch event hosted by the Indian Society of Anesthesiologists took place on November 11, 2025, focusing on education regarding malignant hyperthermia recognition and response protocols [10]